Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 2

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 2
---
examethasone ophthalmic suspension) 0.1%, a steroid eye drop for steroid-responsive
                                            inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment
                                            of the globe.

·IOPIDINE®
                                            1% (apraclonidine hydrochloride) 0.5%, an ophthalmic solution in a sterile isotonic
                                            solution indicated to control or prevent post-surgical elevations in intraocular pressure
                                            that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG
                                            posterior capsulotomy.

·IOPIDINE®
                                            0.5% (apraclonidine hydrochloride) an ophthalmic solution indicated for short-term
                                            adjunctive therapy in patients on maximally tolerated medical therapy who require additional
                                            intraocular pressure (or IOP) reduction.

We
also own U.S. rights to some discontinued products. In February 2024, we announced that we out-licensed Canadian rights for VERKAZIA,
Cationorm® PLUS (a preservative-free formulation for dry eye or allergy relief), VEVYE, ZERVIATE and IHEEZO to Apotex
Inc. (“Apotex”). We also own worldwide rights to NATACYN and FRESHKOTE.

 ImprimisRx 

ImprimisRx is our ophthalmology-focused
pharmaceutical compounding businesses. From its inception in 2014, ImprimisRx, whose business consists of integrated research and development,
production, dispensing/distribution, sales, marketing, and customer-service capabilities, has offered ophthalmologist and optometrist
customers and their patients access to critical medicines to meet their clinical needs. ImprimisRx is focused on compounded medications
to serve needs unmet by commercially available drugs. Our compounded medications include various combinations of drugs formulated into
one bottle and numerous preservative-free formulations. Depending on the formulation, the regulations of a specific state, and ultimately
the needs of the patient, ImprimisRx products may be dispensed as patient-specific medications from our 503A pharmacy, or for in-office
use, made according to current good manufacturing practices (“cGMPs”) or other guidance documents from the FDA, in our FDA-registered
New Jersey outsourcing facility. Our current ophthalmology formulary includes over 30 compounded formulations, many of which are